Author | Roy S. Herbst, MD, PhD | OncLive

Author | Roy S. Herbst, MD, PhD

Articles

Dr. Herbst on the Benefit of Adjuvant Osimertinib in EGFR-Mutant NSCLC

June 02, 2020

Video

Roy S. Herbst, MD, PhD, discusses the benefit of adjuvant osimertinib demonstrated in patients with stage II to IIIA EGFR-mutant non–small cell lung cancer in the phase 3 ADAURA trial.

Dr. Herbst on Combination of Nivolumab and Ipilimumab in Patients With NSCLC

January 22, 2020

Video

Roy S. Herbst, MD, PhD, discusses the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with advanced non–small-cell lung cancer (NSCLC).

Dr. Herbst on Immuno-Oncology Combinations in Lung Cancer

July 26, 2019

Video

Roy S. Herbst, MD, PhD, chief of medical oncology, professor of medicine, Yale Cancer Center, Smilow Cancer Hospital, discusses combinations with immunotherapy in lung cancer.

Dr. Herbst on Immune Resistance in Lung Cancer

November 12, 2018

Video

Roy S. Herbst, MD, PhD, chief of medical oncology, professor of medicine, Yale Cancer Center, Smilow Cancer Hospital, discusses mechanisms of immune resistance for patients with lung cancer.

x